The German medical group Fresenius (FMEG.DE) and the Permira investment fund PERM.UL have made an offer for the medical nutrition arm of Danone (DANO.PA), The Wall Street Journal reported on Wednesday, citing sources close to the matter.
Medical
Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff
Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir Pharmaceuticals Inc for about $3.5 billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent.
AbbVie adds children's AIDS drugs to shared patent pool
U.S. drugmaker AbbVie has added two HIV medicines for children to a shared patent pool in an initiative that should speed the development of cheap new pediatric formulations for use in poor countries.
China drafts policy on emergency Ebola diagnosis, approves products
China has drafted a policy on the emergency use of diagnostic products for the Ebola virus disease and clinical trials, the country's drug regulator said on Friday, as the number of people affected globally by the epidemic nears 16,000.
Medtronic wins conditional EU approval for $43 billion Covidien buy
U.S. medical device maker Medtronic (MDT.N) gained European Union regulatory approval on Friday for its $43 billion takeover of Covidien Plc (COV.N) after agreeing to sell its Irish rival's drug-coated balloon catheter business.
Latest News
Nearly a decade after losing a bidding war for device maker Guidant to Boston Scientific Corp, Johnson & Johnson finally has a chance for payback at a multibillion-dollar trial set to begin on Thursday.
Pfizer (PFE.N) dampened investors' expectations of a renewed bid for AstraZeneca (AZN.L) on Monday by signing a major cancer drug deal with Germany's Merck KGaA (MRCG.DE), reducing the U.S. firm's need for Astra's products.
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014.
The chief executive of Quest Diagnostics Inc (DGX.N) said his company will stick to its core business of diagnostic testing and is not interested in acquiring a contract research organization (CRO), despite such a planned move by rival diagnostics firm LabCorp (LH.N).
AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors.
Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday.
Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc (AZN.L).
Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) on Monday said in a letter to Allergan Inc's (AGN.N) board of directors that it was prepared to raise its offer to at least $200 per share but stopped short of doing so.
Japan's Fujifilm Holdings Corp said on Monday it would buy 49 percent of Texas-based Kalon Biotherapeutics LLC, which has expertise in manufacturing vaccines used against pandemic influenza, Ebola and other public-health threats.
